Literature DB >> 34842193

Peptidylarginine Deiminase and Alzheimer's Disease.

Lai Wang1, Hongyang Chen1, Jing Tang1, Zhengwei Guo1, Yanming Wang1.   

Abstract

Peptidylarginine deiminases (PADs) are indispensable enzymes for post-translational modification of proteins, which can convert Arg residues on the surface of proteins to citrulline residues. The PAD family has five isozymes, PAD1, 2, 3, 4, and 6, which have been found in multiple tissues and organs. PAD2 and PAD4 were detected in cerebral cortex and hippocampus from human and rodent brain. In the central nervous system, abnormal expression and activation of PADs are involved in the pathological changes and pathogenesis of Alzheimer's disease (AD). This article reviews the classification, distribution, and function of PADs, with an emphasis on the relationship between the abnormal activation of PADs and AD pathogenesis, diagnosis, and the therapeutic potential of PADs as drug targets for AD.

Entities:  

Keywords:  Alzheimer’s disease; PAD inhibitors; citrulline; peptidylarginine deiminases

Mesh:

Substances:

Year:  2022        PMID: 34842193     DOI: 10.3233/JAD-215302

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Acute Hypoxia Alters Extracellular Vesicle Signatures and the Brain Citrullinome of Naked Mole-Rats (Heterocephalus glaber).

Authors:  Stefania D'Alessio; Hang Cheng; Liam Eaton; Igor Kraev; Matthew E Pamenter; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208

2.  Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-09-06       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.